Laverock Therapeutics announces in vivo programs in oncology and genetic medicine
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine
Read original article on The Medical News →Related news
-
Research offers new hope for those at higher risk of Alzheimer's disease
United Kingdom
-
Chris Evans Puts His Limelight on a Bonded Dog Pair with Cute Video, Immediately Sees Them Adopted
United Kingdom
-
New mathematical model tracks how tumor environment impacts cancer therapies
United Kingdom
-
Family subsidies struggle to reverse falling birthrates, international comparisons reveal
United Kingdom
-
Brain signals thought to predict events may instead track time
United Kingdom
-
Young adults using AI for health questions may screen positive for anxiety and depression
United Kingdom
-
From binge eating to gaming: When everyday behaviors become addictions
United Kingdom
-
Fractionated radiation reduces brain cancer recurrence and boosts survival
United Kingdom